Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib maintenance in ovarian, peritoneal, or fallopian tube cancer
NCT00263822Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2005
- Primary completion
- Feb 2008
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Erlotinib with Observation (2 arms). Primary endpoint: Progression-Free Survival. Started Sep 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00263822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263822.